Trial Profile
Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation for multiple myeloma. A phase II study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 09 Feb 2023 Status changed from recruiting to completed.
- 16 Feb 2018 New trial record